The company’s financial performance through the third quarter demonstrates a consistent upward trajectory compared to the previous fiscal year. Operating profit rose to ¥298 million, up from ¥262 million a year earlier, while pretax profit reached ¥310 million. These gains were supported by a top-line revenue increase of approximately 3.7%, according to the company's latest financial disclosure prepared under Japanese accounting standards.

Earnings and Shareholder Returns

Profitability metrics showed marked improvement, with earnings per share (EPS) rising to ¥20.44, compared to ¥15.00 in the same period last year. This growth highlights the company’s ability to convert modest revenue gains into substantial net income increases despite the inflationary pressures currently affecting the broader healthcare and pharmaceutical supply chain in Japan.

Regarding shareholder distributions, the board has maintained its dividend policy in line with previous guidance. The company confirmed the following dividend structure for the fiscal year:

• A midyear dividend already paid at ¥2.50 per share.
• A projected year-end dividend of ¥2.50 per share.
• A total forecasted annual payout of ¥5.00 per share.

Chukyo Iyakuhin continues to focus on its core domestic market, maintaining a stable outlook for the remainder of the fiscal year ending March 2025. The company’s ability to sustain these margins will be a key metric for investors as it approaches its full-year reporting cycle.